Vimarsana
Biggest News Aggregation in the World

Page 9 - Preclinical Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Preclinical Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Preclinical Development Today - Breaking & Trending Today

Cidara Therapeutics to Present Ongoing Development of - Vimarsana News

Cidara Therapeutics to Present Ongoing Development of

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit - Vimarsana News

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

SAN DIEGO, June 20, 2023 -- Cidara Therapeutics, Inc. , a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious... | June 20, 2023

Xtalks Announces its Life Science Webinar Calendar for June 2023 - Vimarsana News

Xtalks Announces its Life Science Webinar Calendar for June 2023

Toronto, ON (PRWEB) June 02, 2023 -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical

Source: prweb.com
Kinase Inhibitors for Inflammatory Diseases: Preclinical Development, Upcoming Webinar Hosted by Xtalks - Vimarsana News

Kinase Inhibitors for Inflammatory Diseases: Preclinical Development, Upcoming Webinar Hosted by Xtalks

Toronto, ON (PRWEB) May 25, 2023 -- Protein kinases act as master regulators of multiple key processes within the cell cycle, and aberrant regulation of their

Source: prweb.com
Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Vimarsana News

Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON & SEATTLE--(BUSINESS WIRE)--May 25, 2023--

Source: wsiltv.com